Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.325    0.075 (6.00%)
Bid:
1.25
Ask:
1.40
Spread: 0.15 (12.00%)
Market Cap: £21.27m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

18 Jul 2019 07:00

RNS Number : 9066F
Genedrive PLC
18 July 2019
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

 

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Ian Gilham

 

 

2.

Reason for the notification

a.

Position/status

Non-Executive Chairman

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

19p

51,250

 

d.

Aggregated information

· Aggregated volume

· Price

 

 

N/A

 

e.

Date of the transaction

2019-07-17; UTC time

f.

Place of the transaction

London Stock Exchange, AIM

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO

 

Matthew Fowler: CFO

 

Peel Hunt LLP

+44 (0)207 418 8900

James Steel

 

Oliver Jackson

 

 

Stanford Capital Partners Limited

 

+44 (0)20 3815 8880

 

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

 

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAEXXFSSNEAF
Date   Source Headline
25th Apr 20229:05 amRNSSecond Price Monitoring Extn
25th Apr 20229:00 amRNSPrice Monitoring Extension
20th Apr 20222:00 pmRNSPrice Monitoring Extension
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:35 pmRNSPrice Monitoring Extension
4th Apr 20225:13 pmRNSDirector/PDMR Shareholding
4th Apr 202211:05 amRNSSecond Price Monitoring Extn
4th Apr 202211:00 amRNSPrice Monitoring Extension
4th Apr 20229:05 amRNSSecond Price Monitoring Extn
4th Apr 20229:00 amRNSPrice Monitoring Extension
31st Mar 20229:05 amRNSSecond Price Monitoring Extn
31st Mar 20229:00 amRNSPrice Monitoring Extension
29th Mar 202211:06 amRNSSecond Price Monitoring Extn
29th Mar 202211:00 amRNSPrice Monitoring Extension
29th Mar 202210:00 amRNSNICE issues Medtech Innovation Briefing
29th Mar 20227:00 amRNSHalf-year Report
25th Mar 202211:05 amRNSSecond Price Monitoring Extn
25th Mar 202211:00 amRNSPrice Monitoring Extension
24th Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20224:41 pmRNSSecond Price Monitoring Extn
22nd Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20223:16 pmRNSPALOH study results published in JAMA Pediatrics
21st Mar 20229:05 amRNSSecond Price Monitoring Extn
21st Mar 20229:00 amRNSPrice Monitoring Extension
18th Mar 20224:41 pmRNSSecond Price Monitoring Extn
18th Mar 20224:36 pmRNSPrice Monitoring Extension
18th Mar 20222:05 pmRNSSecond Price Monitoring Extn
18th Mar 20222:00 pmRNSPrice Monitoring Extension
18th Mar 20222:00 pmRNSFirst NHS Deployments of Genedrive System for AIHL
17th Mar 20227:00 amRNSBoard appointment
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:35 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSFurther re Directorate Change
23rd Feb 20225:00 pmRNSDirector/PDMR Shareholding
23rd Feb 20229:05 amRNSSecond Price Monitoring Extn
23rd Feb 20229:00 amRNSPrice Monitoring Extension
23rd Feb 20227:00 amRNSUpdate on Point of Care Covid Test
15th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSNotice of Results
21st Jan 202211:05 amRNSSecond Price Monitoring Extn
21st Jan 202211:00 amRNSPrice Monitoring Extension
20th Jan 20224:40 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
10th Jan 20229:06 amRNSSecond Price Monitoring Extn
10th Jan 20229:00 amRNSPrice Monitoring Extension
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:01 pmRNSPrice Monitoring Extension
30th Dec 202111:20 amRNSResult of AGM
30th Dec 20219:05 amRNSSecond Price Monitoring Extn
30th Dec 20219:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.